SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 39.26 |
| Enterprise Value ($M) | 36.48 |
| Book Value ($M) | 2.78 |
| Book Value / Share | 0.18 |
| Price / Book | 14.13 |
| NCAV ($M) | 1.35 |
| NCAV / Share | 0.09 |
| Price / NCAV | 29.02 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -5.56 |
| Return on Assets (ROA) | -0.97 |
| Return on Equity (ROE) | -1.02 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.63 |
| Current Ratio | 1.63 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 3.79 |
| Assets | 5.21 |
| Liabilities | 2.43 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | LFP Management, LLC | 5.40 | ||
| 13G | Bender Lewis H | 16.10 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 7,414 | 28,457 | 26.05 | |
| 11,473 | 37,717 | 30.42 | |
| 17,347 | 84,464 | 20.54 | |
| 3,944 | 8,972 | 43.96 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INKT – MiNK Therapeutics, Inc. | INM – InMed Pharmaceuticals Inc. |
| INMB – INmune Bio, Inc. | IRD – Opus Genetics, Inc. |
| ITRM – Iterum Therapeutics plc |
Financial data and stock pages provided by
Fintel.io